Dr Oscar R Rivera, DDS | |
2 N Euclid Ave Suite #a B C, National City, CA 91950-1967 | |
(619) 205-6363 | |
(619) 263-4247 |
Full Name | Dr Oscar R Rivera |
---|---|
Gender | Male |
Speciality | Anesthesiologist Assistant |
Location | 2 N Euclid Ave Suite #a B C, National City, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619071883 | NPI | - | NPPES |
FHC70961F | Other | MEDI-CAL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367H00000X | Anesthesiologist Assistant | OSC 445 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Oscar R Rivera, DDS 4004 Beyer Blvd, San Ysidro, CA 92173-2007 Ph: (619) 428-4463 | Dr Oscar R Rivera, DDS 2 N Euclid Ave Suite #a B C, National City, CA 91950-1967 Ph: (619) 205-6363 |
News Archive
DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate was an award recipient at the 6th October ceremony held in Paris, France.
Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.
Where you live in Canada may play a role in your risk of major diseases like cardiovascular disease, diabetes and cancer.
The strict regulations governing the prescription and use of the acne drug isotretinoin, sold by Roche under the brand name Accutane, are affecting the drug's sale and dispensation and raising concerns about sales of the medication over the Internet, the Wall Street Journal reports (Corbett Dooren, Wall Street Journal, 9/12).
Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.
› Verified 2 days ago